Business context and reporting period
The supplied filing is Oxygen Biotherapeutics, Inc.’s Form 10-K for the fiscal year ended April 30, 2012—not a Tenax Therapeutics filing or a 2010 Q4 report. The company was a development-stage biotechnology business focused on oxygen-delivery products, particularly Oxycyte for traumatic brain injury, and topical products including Dermacyte and Wundecyte. It reported no significant product revenue.
Financial performance and position
| Metric | FY2012 | FY2011 |
|---|---|---|
| Product revenue | $100,519 | $322,349 |
| Government grant revenue | $314,515 | $0 |
| Total net revenue | $363,781 | $103,167 |
| Gross profit on product revenue | $49,266; 49% margin | $103,167; 32% margin |
| Operating expenses | $8,583,978 | $10,665,844 |
| Net operating loss | $8,220,197 | $10,562,677 |
| Interest expense | $7,412,054 | $171,563 |
| Net loss | $15,712,410 | $10,448,296 |
| Net loss per share, basic | $0.61 | $0.45 |
| Cash used in operating activities | $8,278,366 | $8,403,142 |
Product revenue fell 69%, mainly amid a suspension of the existing marketing program and a focus on reformulation and repackaging. Product gross margin rose to 49% from 32%, which the company attributed to a greater share of sales through wholesale and retail channels. Grant revenue partially offset lower product sales; $244,013 of grant-related costs reimbursed in advance was recorded as deferred revenue. The higher net loss reflected a sharp increase in interest expense, including non-cash debt-discount amortization, preferred-stock fair-value and conversion charges, and the premium recognized on prepayment of notes.
At April 30, 2012, cash and cash equivalents were $1,879,872; current assets were $2,631,032; and working capital was negative $495,838. Total assets were $4,141,934, total liabilities $4,487,980, and stockholders’ deficit $346,046. Notes payable, net, totaled approximately $1.424 million, including $1.361 million long term; the $4.9 million principal convertible notes were substantially offset by an unamortized discount. Series A preferred stock was recorded as a $1,247,266 current liability. Accumulated deficit was $107.6 million.
Financing activities provided $9,467,440 in cash, including proceeds from convertible notes, preferred stock and other financing, while investing activities used $261,146. Cash increased by $927,928 during the year.
Material changes versus the prior year
- Net loss increased 50% to $15.7 million, despite a 20% reduction in operating expenses; interest expense rose by $7.2 million.
- Product revenue declined by $221,830, while grant revenue contributed $314,515 for the first time in the comparison presented.
- Research and development expense declined 8% to $2.46 million, mainly because Phase II-B trial costs were lower.
- The company prepaid its Vatea notes in November 2011 using proceeds from an $8 million equity closing, recognizing a substantial related premium in interest expense.
- The December 2011 preferred-stock offering began with $3.5 million; an additional $2.5 million closed in June 2012, with up to $1.5 million more scheduled subject to conditions.
Outlook, risks and unusual items
- Liquidity and going concern: Management said available funds, including the June 2012 preferred-stock proceeds, were expected to fund operations through December 31, 2012. If the remaining offering conditions were met, management estimated runway through March 31, 2013. The auditor’s report raised substantial doubt about the company’s ability to continue as a going concern. Additional financing is necessary; availability and terms are uncertain.
- Oxycyte: The FDA had placed the U.S. Phase II protocol on clinical hold over safety concerns. The company was pursuing safety-related studies supported by a $2.07 million U.S. Army award and conducting Phase II-B work abroad. Enrollment had been paused for protocol, supply and site review; management targeted resuming the second cohort in fiscal Q3 2013. Phase III testing and regulatory approval would still be required.
- Commercial products: Dermacyte sales remained limited, and the company narrowed sales efforts to North Carolina and South Florida. Exclusive European and Mexican distributor agreements were terminated after minimum purchase requirements were not met. Wundecyte’s FDA submission was viewed as likely to require combination-device development, including extensive additional studies.
- Financing terms and dilution: Preferred stock carried a 7% annual dividend and restrictive covenants. Certain triggering events could increase the dividend rate to 15% and require cash redemption at 125% of the outstanding conversion amount or a potentially higher formula. As of July 20, 2012, the company disclosed approximately 9.6 million shares potentially issuable under convertible or exercisable instruments, about 31% of then-outstanding common shares.
- Contingencies: The company accrued approximately $550,000 for potential Section 409A-related liabilities and estimated unfavorable outcomes could exceed the recorded amount by approximately $500,000. In the Tenor lawsuit, a July 2012 court order found the company had breached a right-of-first-offer agreement; a jury was to determine any damages.
- Management: Michael B. Jebsen served as interim CEO and CFO while the company searched for a permanent CEO. Management reported effective disclosure controls and internal control over financial reporting as of April 30, 2012.
Important facts investors should verify
- Confirm the filing identity and period: this text is Oxygen Biotherapeutics’ FY2012 10-K, despite the request metadata naming Tenax Therapeutics and 2010 Q4.
- Check actual cash burn, financing proceeds and runway after the June 2012 closing, including whether the conditional September offering closing occurred.
- Verify the current status, enrollment and safety findings of Oxycyte studies, and whether FDA concerns have been resolved.
- Review the preferred-stock redemption, dividend, covenant and conversion terms, and resulting dilution.
- Monitor the Tenor damages outcome and final exposure related to the Section 409A matter.